Literature DB >> 11479214

Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.

S Oesterreich1, P Zhang, R L Guler, X Sun, E M Curran, W V Welshons, C K Osborne, A V Lee.   

Abstract

Estrogen can increase insulin-like growth factor-I receptor (IGF-IR) and insulin receptor substrate-1 (IRS-1) expression, two key components of IGF-I-mediated signaling. The result is sensitization of breast cancer cells to IGF-I and synergistic growth in the presence of estrogen and IGF-I. We hypothesized that loss of estrogen receptor alpha (ERalpha) would result in reduced IGF-mediated signaling and growth. To test this hypothesis, we examined IGF-I effects in MCF-7 breast cancer cell sublines that have been selected for loss of ERalpha (C4 and C4-12 cells are ERalpha-negative) by long-term estrogen withdrawal. C4 and C4-12 cells had reduced IGF-IR and IRS-1 mRNA and protein expression (compared with MCF-7 cells) that was not inducible by estrogen. Furthermore, C4 and C4-12 cells showed reduced IGF-I signaling and failed to show any growth response to either estrogen or IGF-I. To prove that loss of IGF and estrogen-mediated signaling and growth was a consequence of loss of ERalpha, we re-expressed ERalpha in C4-12 cells by stable transfection with HA-tagged ERalpha. Three independent C4-12 ERalpha-HA clones expressed a functional ERalpha that (a) was down-regulated by estrogen, (b) conferred estrogen-induction of cyclin D1 expression, and (c) caused estrogen-mediated increase in the number of cells in S phase. All of the effects were completely blocked by antiestrogens. Interestingly, ERalpha-HA expression in C4-12 cells did not restore estrogen induction of progesterone receptor expression. However, ERalpha-positive C4-12 cells now exhibited estrogen-induction of IGF-IR and IRS-1 levels and responded mitogenically to both estrogen and IGF-I. These data show that ERalpha is a critical requirement for IGF signaling, and to our knowledge this is the first report of functional ERalpha expression that confers estrogen-mediated growth of an ER-negative breast cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479214

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Growth factor regulation of cell cycle progression in mammary epithelial cells.

Authors:  Malinda A Stull; Anne M Rowzee; Aimee V Loladze; Teresa L Wood
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 2.  Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation.

Authors:  S Hüser; S Guth; H G Joost; S T Soukup; J Köhrle; L Kreienbrock; P Diel; D W Lachenmeier; G Eisenbrand; G Vollmer; U Nöthlings; D Marko; A Mally; T Grune; L Lehmann; P Steinberg; S E Kulling
Journal:  Arch Toxicol       Date:  2018-08-21       Impact factor: 5.153

Review 3.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

4.  Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.

Authors:  Yasir H Ibrahim; Sara A Byron; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

5.  Long-range transcriptional control of progesterone receptor gene expression.

Authors:  Jamie Bonéy-Montoya; Yvonne S Ziegler; Carol D Curtis; Jonathan A Montoya; Ann M Nardulli
Journal:  Mol Endocrinol       Date:  2009-12-01

6.  Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Authors:  Guangliang Li; Jing Zhang; Ketao Jin; Kuifeng He; Yi Zheng; Xin Xu; Haohao Wang; Haiyong Wang; Zhongqi Li; Xiongfei Yu; Xiaodong Teng; Jiang Cao; Lisong Teng
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

7.  Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.

Authors:  Nicholas B Berry; Meiyun Fan; Kenneth P Nephew
Journal:  Mol Endocrinol       Date:  2008-04-03

8.  Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.

Authors:  Ben A Hall; Tae Yeon Kim; Maxwell N Skor; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2012-07-29       Impact factor: 4.872

Review 9.  The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.

Authors:  Morteza Motallebnezhad; Leili Aghebati-Maleki; Farhad Jadidi-Niaragh; Hamid Nickho; Hosein Samadi-Kafil; Karim Shamsasenjan; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2016-07-21

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.